Reduction of cerebral glucose utilization by the HIV envelope glycoprotein Gp-120.
Gp-120 is a glycoprotein constituent of the human immunodeficiency virus (HIV) envelope. The effects of gp-120 on cerebral glucose utilization in rats were studied by the quantitative 2-deoxy-D-[1-14C] glucose method. Intracerebroventricular injection of gp-120 significantly reduced glucose utilization in the lateral habenula and the suprachiasmatic nucleus and decreased the global cerebral metabolic rate for glucose. The findings suggest that gp-120 and closely related peptides can alter neuronal function, thereby contributing to the sequelae of HIV infection.
Kimes
A S
AS
Neuropharmacology Laboratory, National Institute on Drug Abuse, Baltimore, Maryland 21224.
London
E D
ED
Szabo
G
G
Raymon
L
L
Tabakoff
B
B
D000704:Analysis of Variance; D000818:Animals; D001345:Autoradiography; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002250:Carbon Radioisotopes; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D003847:Deoxyglucose / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000378:metabolism*; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000494:pharmacology*; D007276:Injections, Intraventricular; D008297:Male; D009928:Organ Specificity; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values
D002250:Carbon Radioisotopes; D015699:HIV Envelope Protein gp120; D003847:Deoxyglucose; D005947:Glucose